NASDAQ:BTAI BioXcel Therapeutics (BTAI) Stock Price, News & Analysis $0.07 +0.00 (+0.27%) As of 09/4/2026 This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About BioXcel Therapeutics Stock (NASDAQ:BTAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioXcel Therapeutics alerts:Sign Up Key Stats Today's Range$0.07▼$0.0950-Day Range$0.07▼$1.1952-Week Range$0.07▼$4.29Volume42.29 million shsAverage Volume17.36 million shsMarket Capitalization$2.32 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingHold Company Overview BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for neuroscience and immuno-oncology indications. The company uses an artificial intelligence-driven drug development platform to identify and advance therapies by analyzing existing clinical and biomedical data, with the goal of improving the efficiency of drug discovery and development. BioXcel’s primary commercial product is IGALMI (dexmedetomidine) sublingual film, which the U.S. Food and Drug Administration approved in 2022 for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. The product is designed for administration under the tongue and is intended for use in a monitored healthcare setting. BioXcel Therapeutics is headquartered in New Haven, Connecticut, and has focused its clinical and commercial activities primarily on the U.S. market. The company was led by co-founder and Chief Executive Officer Vimal Mehta, who has overseen its efforts to develop AI-enabled therapies and expand the use of its neuroscience-focused product portfolio.AI Generated. May Contain Errors. Read More BioXcel Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreBTAI MarketRank™: BioXcel Therapeutics scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingBioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBioXcel Therapeutics has a consensus price target of $11.00, representing about 14,744.8% upside from its current price of $0.07.Amount of Analyst CoverageBioXcel Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about BioXcel Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($2.70) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioXcel Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.32% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 0.85, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioXcel Therapeutics has recently increased by 84.80%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.49 News SentimentBioXcel Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioXcel Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for BTAI on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.MarketBeat Follows2 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.70% of the stock of BioXcel Therapeutics is held by insiders.Percentage Held by Institutions30.68% of the stock of BioXcel Therapeutics is held by institutions.Read more about BioXcel Therapeutics' insider trading history. Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BTAI Stock News HeadlinesAnalyzing BioXcel Therapeutics (NASDAQ:BTAI) & Voyager Therapeutics (NASDAQ:VYGR)September 20 at 3:58 AM | americanbankingnews.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Grows By 84.8%September 16, 2026 | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 22 at 1:00 AM | Porter & Company (Ad)Biotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive GainsSeptember 3, 2026 | rttnews.comBioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from S&P TMI IndexSeptember 2, 2026 | marketscreener.comMBioXcel Therapeutics Enters Asset Sale Agreement With Teva Pharmaceuticals; Stock DownAugust 31, 2026 | rttnews.comBioXcel Therapeutics Initiates Chapter 11 and Sale ProcessAugust 30, 2026 | theglobeandmail.comBioXcel Therapeutics Agrees To Teva Asset SaleAugust 28, 2026 | rttnews.comSee More Headlines BTAI Stock Analysis - Frequently Asked Questions How have BTAI shares performed this year? BioXcel Therapeutics' stock was trading at $1.60 at the start of the year. Since then, BTAI stock has decreased by 95.4% and is now trading at $0.0741. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) released its quarterly earnings data on Thursday, August, 13th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by $0.05. The company earned $0.18 million during the quarter, compared to analyst estimates of $0.49 million. When did BioXcel Therapeutics' stock split? BioXcel Therapeutics shares reverse split before market open on Monday, February 10th 2025.The 1-16 reverse split was announced on Thursday, February 6th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did BioXcel Therapeutics IPO? BioXcel Therapeutics (BTAI) raised $65 million in an IPO on Thursday, March 8th 2018. The company issued 5,454,545 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are BioXcel Therapeutics' major shareholders? BioXcel Therapeutics' top institutional investors include Headlands Technologies LLC (0.08%). Insiders that own company stock include Vimal Mehta, Richard I Steinhart, Frank Yocca and Vincent O'neill. View institutional ownership trends. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioXcel Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE) and Saia (SAIA). Company Calendar Last Earnings8/13/2026Today9/22/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 BTAI's financial health is in the Red zone, according to TradeSmith. BTAI has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BTAI CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees90Year Founded2017Price Target and Rating Average Price Target for BioXcel Therapeutics$11.00 High Price Target$17.00 Low Price Target$5.00 Potential Upside/Downside+14,744.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.90 million Net Margins-9,549.87% Pretax Margin-9,549.87% Return on EquityN/A Return on Assets-185.82% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual Sales$640 thousand Price / Sales3.63 Cash FlowN/A Price / Cash FlowN/A Book Value($4.37) per share Price / Book-0.02Miscellaneous Outstanding Shares31,310,000Free Float30,148,000Market Cap$2.32 million OptionableNo Data Beta0.19 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:BTAI) was last updated on 9/22/2026 by MarketBeat.com Staff. From Our PartnersChina's dominance in rare earth processing sparks new defense rulesOn January 1, 2027, new Pentagon rules tighten sourcing restrictions on critical minerals tied to foreign adve...The Tomorrow Investor | Sponsored$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the infrastructure layer beneath the AI boom, from GPU hardware ...Trading Wire | SponsoredInside Nevada's 60 Million Ounce Gold CorridorBarrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourm...Wall Street Logic | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredPass by August 7… or wait until 2027?On August 14, federal regulators cleared a national trust bank tied to the Trump family's crypto venture. W...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
